Home > News > pSivida Limited Describes Strategy for Further Clinical Trials
February 18th, 2005
pSivida Limited Describes Strategy for Further Clinical Trials
Abstract:
Dr. Aston discusses the importance of the recently-announced successful Phase IIa clinical trials of the company's lead product, BrachySil(TM) for liver cancer, as well as the company's plans for clinical trials and commercialization of the product. In the most recent trial, it was demonstrated that BrachySil(TM) is safe and effective in tumor regression with increased efficacy.
Source:
businesswire
Related News Press |
Possible Futures
Closing the gaps — MXene-coating filters can enhance performance and reusability February 28th, 2025
Rice researchers harness gravity to create low-cost device for rapid cell analysis February 28th, 2025
Nanomedicine
Multiphoton polymerization: A promising technology for precision medicine February 28th, 2025
Rice researchers harness gravity to create low-cost device for rapid cell analysis February 28th, 2025
SMART researchers pioneer first-of-its-kind nanosensor for real-time iron detection in plants February 28th, 2025
Announcements
Closing the gaps — MXene-coating filters can enhance performance and reusability February 28th, 2025
Rice researchers harness gravity to create low-cost device for rapid cell analysis February 28th, 2025
![]() |
||
![]() |
||
The latest news from around the world, FREE | ||
![]() |
![]() |
||
Premium Products | ||
![]() |
||
Only the news you want to read!
Learn More |
||
![]() |
||
Full-service, expert consulting
Learn More |
||
![]() |